CMC(SH:603122) Sou Hu Cai Jing·2025-03-31 11:29Group 1 - The core viewpoint of the articles indicates that 合富中国 (Hefei China) is experiencing a significant decline in stock price and financial performance, with a current PE ratio of 98.34, which is substantially higher than the industry average of 22.15 [1][2] - As of the 2024 annual report, 合富中国 reported a revenue of 939 million yuan, representing a year-on-year decrease of 14.05%, and a net profit of 27.57 million yuan, down 41.58% from the previous year [1] - The company operates primarily in the field of in vitro diagnostic medical devices and related consumables, with its main products being concentrated in the in vitro diagnostic product business and medical product distribution [1] Group 2 - The total market capitalization of 合富中国 is 2.711 billion yuan, with 15 institutions holding shares, including 12 funds, totaling 5.0924 million shares valued at 36 million yuan [1] - In terms of industry comparison, 合富中国 ranks 28th in terms of PE ratio within the pharmaceutical commercial sector, where the median PE ratio is 17.56 [1][2] - The sales gross margin for 合富中国 stands at 19.60%, indicating the profitability of its sales relative to its revenue [1]